Moracizine

Jump to navigation Jump to search
Moracizine
Moracizine.png
Clinical data
Trade namesEthmozine
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa601214
Pregnancy
category
ATC code
Pharmacokinetic data
Bioavailability34–38%
Protein binding95%
Elimination half-life3–4 hours (healthy volunteers), 6–13 hours (cardiac disease)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H25N3O4S
Molar mass427.518 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Moracizine

Articles

Most recent articles on Moracizine

Most cited articles on Moracizine

Review articles on Moracizine

Articles on Moracizine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Moracizine

Images of Moracizine

Photos of Moracizine

Podcasts & MP3s on Moracizine

Videos on Moracizine

Evidence Based Medicine

Cochrane Collaboration on Moracizine

Bandolier on Moracizine

TRIP on Moracizine

Clinical Trials

Ongoing Trials on Moracizine at Clinical Trials.gov

Trial results on Moracizine

Clinical Trials on Moracizine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Moracizine

NICE Guidance on Moracizine

NHS PRODIGY Guidance

FDA on Moracizine

CDC on Moracizine

Books

Books on Moracizine

News

Moracizine in the news

Be alerted to news on Moracizine

News trends on Moracizine

Commentary

Blogs on Moracizine

Definitions

Definitions of Moracizine

Patient Resources / Community

Patient resources on Moracizine

Discussion groups on Moracizine

Patient Handouts on Moracizine

Directions to Hospitals Treating Moracizine

Risk calculators and risk factors for Moracizine

Healthcare Provider Resources

Symptoms of Moracizine

Causes & Risk Factors for Moracizine

Diagnostic studies for Moracizine

Treatment of Moracizine

Continuing Medical Education (CME)

CME Programs on Moracizine

International

Moracizine en Espanol

Moracizine en Francais

Business

Moracizine in the Marketplace

Patents on Moracizine

Experimental / Informatics

List of terms related to Moracizine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Moracizine (INN,[1] or moricizine, trade name Ethmozine) is an antiarrhythmic of class IC.[2] It was used for the prophylaxis and treatment of serious and life-threatening ventricular arrhythmias,[3] but was withdrawn in 2007 for commercial reasons.[4]

Pharmacology

Moracizine, a phenothiazine derivative, undergoes extensive first-pass metabolism and is also extensively metabolized after it has entered the circulation. It may have pharmacologically active metabolites. A clinical study has shown that moracizine is slightly less effective than encainide or flecainide in suppressing ventricular premature depolarizations.[citation needed] Compared with disopyramide and quinidine, moracizine was equally or more effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia.[citation needed]

In the Cardiac Arrhythmia Suppression Trial (CAST), a large study testing the influence of antiarrhythmics on mortality, showed a non-significant increase of mortality from 5.4 to 7.2% under moracizine. This is in line with other class IC antiarrhythmics.[5]

References

  1. "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). World Health Organization. 2009. p. 103.
  2. PMID 12402511 (PMID 12402511)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  3. British National Formulary (59th ed.). British Medical Journal Publishing Group, Pharmaceutical Press. 2010.
  4. "Shire Announces Ethmozine will be Available until December 31, 2007". Heart Rhythm Society.
  5. PMID 1377359 (PMID 1377359)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

Template:Antiarrhythmic agents